Compare MPT & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPT | SRPT |
|---|---|---|
| Founded | 2003 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2004 | 2000 |
| Metric | MPT | SRPT |
|---|---|---|
| Price | $3.92 | $22.14 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 29 |
| Target Price | $5.00 | ★ $25.85 |
| AVG Volume (30 Days) | ★ 7.8M | 2.9M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.43% | N/A |
| EPS Growth | ★ 88.56 | N/A |
| EPS | 0.05 | ★ 2.99 |
| Revenue | $972,022,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.91 | N/A |
| P/E Ratio | $79.80 | ★ $7.00 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $3.89 | $14.68 |
| 52 Week High | $6.47 | $25.32 |
| Indicator | MPT | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 34.30 | 61.76 |
| Support Level | N/A | $20.12 |
| Resistance Level | $5.32 | $23.71 |
| Average True Range (ATR) | 0.11 | 1.53 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 20.31 | 73.51 |
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. Its business strategy is to acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear of the costs associated with the property. The group's geographic areas are the United States, the United Kingdom, and All other countries.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.